S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96
S&P 500   3,831.39
DOW   30,967.82
QQQ   286.96

CymaBay Therapeutics Stock Forecast, Price & News

+0.24 (+8.66%)
(As of 07/5/2022 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
499,535 shs
Average Volume
1.14 million shs
Market Capitalization
$254.89 million
P/E Ratio
Dividend Yield
Price Target

CymaBay Therapeutics MarketRank™ Forecast

Analyst Rating
3.25 Rating Score
258.8% Upside
$10.80 Price Target
Short Interest
5.65% of Float Sold Short
Dividend Strength
Upright™ Environmental Score
News Sentiment
1.28mentions of CymaBay Therapeutics in the last 14 days
Based on 2 Articles This Week
Insider Trading
Acquiring Shares
$100,037 Bought Last Quarter
Proj. Earnings Growth
From ($1.23) to ($1.29) Per Share

Overall MarketRank

MarketRank is calculated as 30% analysis score, 20% valuation score, 10% short interest score, 10% dividend score, 10% sustainability score, 10% news and social score, and 10% insider trading score.

2.52 out of 5 stars

Medical Sector

88th out of 1,426 stocks

Pharmaceutical Preparations Industry

29th out of 682 stocks

30 days | 90 days | 365 days | Advanced Chart

Receive CBAY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for CymaBay Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

CymaBay Therapeutics logo

About CymaBay Therapeutics (NASDAQ:CBAY) Stock

CymaBay Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and providing therapies to treat liver and other chronic diseases. Its lead product candidate is seladelpar (MBX-8025), a selective agonist of peroxisome proliferator activated receptor delta that is in phase III clinical study for the treatments of primary biliary cholangitis (PBC), as well as has completed Phase 2b clinical study to treat patients with nonalcoholic steatohepatitis. The company also develops MBX-2982, which is in Phase 2a clinical study for the disease/condition of hypoglycemia in type 1 diabetics. It has a license agreement with ABW Cyclops SPV LP to support development of seladelpar for the treatment of PBC; and holds a worldwide license from Janssen Pharmaceuticals, Inc. to research, develop, and commercialize compounds with activity against an undisclosed metabolic disease target. The company was formerly known as Metabolex, Inc. CymaBay Therapeutics, Inc. was incorporated in 1988 and is headquartered in Newark, California.

CBAY Stock News Headlines

CymaBay Therapeutics: Q1 Earnings Insights
CymaBay Therapeutics Q4 2021 Earnings Preview
See More Headlines

Industry, Sector and Symbol

Pharmaceutical preparations
Current Symbol
Year Founded

Company Calendar

Last Earnings
Next Earnings (Estimated)
Fiscal Year End

Price Target and Rating

Average Stock Price Forecast
High Stock Price Forecast
Low Stock Price Forecast
Forecasted Upside/Downside
Consensus Rating
Rating Score (0-4)
Research Coverage
4 Analysts


Net Income
Pretax Margin


Sales & Book Value

Annual Sales
Book Value
$1.93 per share


Free Float
Market Cap
$254.89 million

CymaBay Therapeutics Frequently Asked Questions

Should I buy or sell CymaBay Therapeutics stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for CymaBay Therapeutics in the last year. There are currently 3 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" CymaBay Therapeutics stock.
View analyst ratings for CymaBay Therapeutics
or view top-rated stocks.

What is CymaBay Therapeutics' stock price forecast for 2022?

4 brokerages have issued 1-year price targets for CymaBay Therapeutics' stock. Their CBAY stock forecasts range from $8.00 to $14.00. On average, they anticipate CymaBay Therapeutics' share price to reach $10.80 in the next twelve months. This suggests a possible upside of 258.8% from the stock's current price.
View analysts' price targets for CymaBay Therapeutics
or view top-rated stocks among Wall Street analysts.

How has CymaBay Therapeutics' stock performed in 2022?

CymaBay Therapeutics' stock was trading at $3.38 at the beginning of the year. Since then, CBAY stock has decreased by 10.9% and is now trading at $3.01.
View the best growth stocks for 2022 here

When is CymaBay Therapeutics' next earnings date?

CymaBay Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for CymaBay Therapeutics

How were CymaBay Therapeutics' earnings last quarter?

CymaBay Therapeutics, Inc. (NASDAQ:CBAY) released its earnings results on Thursday, May, 12th. The biopharmaceutical company reported ($0.32) earnings per share for the quarter, missing analysts' consensus estimates of ($0.31) by $0.01. During the same period last year, the company posted ($0.25) earnings per share.
View CymaBay Therapeutics' earnings history

Who are CymaBay Therapeutics' key executives?

CymaBay Therapeutics' management team includes the following people:
  • Mr. Sujal A. Shah, Pres, CEO & Director (Age 49, Pay $873.87k)
  • Dr. Dennis D. Kim M.B.A., M.D., MBA, Chief Medical Officer (Age 52, Pay $406.11k)
  • Mr. Lewis J. Stuart B.A., BA, M.B.A., MBA, Chief Commercial Officer (Age 63, Pay $378.79k)
  • Mr. Daniel Menold, VP of Fin. (Age 52)
  • Dr. Charles A. McWherter Ph.D., Sr. VP & Chief Scientific Officer (Age 67)
  • Mr. Paul T. Quinlan, Gen. Counsel, Chief Compliance Officer & Corp. Sec. (Age 59)
  • Mr. Ken Boehm, Sr. VP of HR
  • Mr. Patrick J. O'Mara, Sr. VP of Bus. Devel. (Age 61)
  • Dr. Robert L. Martin, Sr. VP of Manufacturing & Nonclinical Devel. (Age 60)
  • Ms. Klara A. Dickinson-Eason, Chief Regulatory & Quality Assurance Officer (Age 54)

What other stocks do shareholders of CymaBay Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other CymaBay Therapeutics investors own include Sorrento Therapeutics (SRNE), NVIDIA (NVDA), Advanced Micro Devices (AMD), OPKO Health (OPK), Pfizer (PFE), Alibaba Group (BABA), Novavax (NVAX), Corbus Pharmaceuticals (CRBP), Energy Transfer (ET) and Viking Therapeutics (VKTX).

What is CymaBay Therapeutics' stock symbol?

CymaBay Therapeutics trades on the NASDAQ under the ticker symbol "CBAY."

How do I buy shares of CymaBay Therapeutics?

Shares of CBAY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is CymaBay Therapeutics' stock price today?

One share of CBAY stock can currently be purchased for approximately $3.01.

How much money does CymaBay Therapeutics make?

CymaBay Therapeutics (NASDAQ:CBAY) has a market capitalization of $254.89 million. The biopharmaceutical company earns $-90,000,000.00 in net income (profit) each year or ($1.33) on an earnings per share basis.

How many employees does CymaBay Therapeutics have?

CymaBay Therapeutics employs 59 workers across the globe.

How can I contact CymaBay Therapeutics?

CymaBay Therapeutics' mailing address is 7575 GATEWAY BOULEVARD SUITE 110, NEWARK CA, 94560. The official website for CymaBay Therapeutics is www.cymabay.com. The biopharmaceutical company can be reached via phone at (510) 293-8800, via email at investors@cymabay.com, or via fax at 510-293-9090.

This page (NASDAQ:CBAY) was last updated on 7/6/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer.